deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05130827

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Pilot Trial of Plinabulin and Pegfilgrastim to Reduce the Duration of Absolute Neutropenia After Autologous Hematopoietic Cell Transplantation for Patients With Multiple Myeloma

Sponsor: BeyondSpring Pharmaceuticals Inc.

Conditions Multiple Myeloma
Interventions Plinabulin
Updated 13 times since 2021 Last updated: Dec 23, 2025 Started: Dec 21, 2021 Primary completion: Nov 30, 2026 Completion: Nov 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05130827, this PHASE2 trial focuses on Multiple Myeloma and remains ongoing. Sponsored by BeyondSpring Pharmaceuticals Inc., it has been updated 13 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Nov 2022 · 4 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Aug 2023 · 7 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 8 months · monthly snapshot

Change History

13 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 8 earlier versions

  1. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  2. Jan 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  3. Nov 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  4. Jul 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  5. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  6. Feb 2022 — May 2022 [monthly]

    Recruiting PHASE2

  7. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeyondSpring Pharmaceuticals Inc.
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations